Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Next Previous
X
Search
Trial Profile

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perillyl alcohol (Primary)
  • Indications Astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NEONC Technologies

    • Most Recent Events

    • 23 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2024.
    • 23 Sep 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
    • 27 Jan 2022 According to ClinicalTrials.gov record, protocol has been amended to increase in number of treatment arms from 1 to 2.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top